Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

NCT06607926 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Resectable Non-Small-Cell Lung Cancer

Interventions

DRUG: Thymosin Alpha 1
DRUG: Tislelizumab
DRUG: Platinum-doublet chemotherapy

Sponsor

Xuanwu Hospital, Beijing